论文部分内容阅读
本文报告用胡芦素片合并化疗药物治疗原发性肝癌44例,治后一年生存率47.7％(21/44),中位生存期12个月,平均生存期12.5±7.54月,比同期单用同一化疗方案对照组—一年生存率9％(4/44),中位5月,平均6.1±7.12月,有非常显著差异(P<0.01)。且胡芦素组尚有8例存活,而后者仅2例。胡芦素片提取自中药甜瓜蒂(Cucumis melo),动物实验表明有护肝、抑癌、抗肝纤维增加和提高免疫功能作用,或与抗癌药并用有协同作用而增加疗效。
This paper reports 44 cases of hepatocellular carcinoma treated with fenugreek tablets and chemotherapeutic drugs. The one-year survival rate after treatment was 47.7% (21/44), the median survival period was 12 months, and the average survival time was 12.5±7.54 months, which was comparable to the same period. In the control group with the same chemotherapy regimen alone, the one-year survival rate was 9% (4/44), and the median time was 5 months, with an average of 6.1 ± 7.12 months. There was a very significant difference (P < 0.01). In addition, 8 cases survived in the fluocinolone group and only 2 cases in the latter group. Hulusu tablets were extracted from the traditional Chinese medicine Cucumis melo. Animal experiments showed that there are liver protection, cancer suppression, anti-hepatic fibers increase and immune function, or synergy with anticancer drugs and increase the efficacy.